Experience

Eloxx Pharmaceuticals

• United States
• Biotechnology Research
• 1 - 100 Employee

• Associate Director/Senior Research Fellow

  • May 2015 - Present

  Drug Discovery by Total Synthesis and Semi-Synthesis of Macrolides Designed and synthesized a macrolide ZKN-0013 as IND candidate for RDEB (Recessive Dystrophic Epidermolysis Bullosa), expect to submit an IND application in early 2023. ZKN-0013 is also an IND candidate for FAP (Familial Adenomatous Polyposis), expect to submit an IND application in the second half of 2023. Designed and synthesized another macrolide as IND candidate against Gram-negative bacteria targeting UTI, IND application was deferred due to business strategy Designed and developed an novel synthetic route to scale up above two compounds for animal studies and clinic trials. • Overcame the issue of highly pyrophoric reagent and made the large-scale production feasible. • Solved the problem of huge solvent volume (1/300 w/v) and made the manufacture production doable. Solvent volume is reduced to (1/30w/v). • Reduced 11 synthetic steps, no column was used for purification • Increased the total yield 10 times and reduced the cost more than 15 times Synthesized active compounds in oncology project for the identification of ribosome modulating small molecules efficacious against several cancer types Synthesized active compounds in cystic fibrosis (CF) project



Bristol Myers Squibb

• United States
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Senior Investigator II

  • Apr 1999 - Nov 2013

  Led a medicinal chemistry team in the execution of numerous early phase programs in both neuroscience and virology areas. As a lead chemist in the execution of full-phase programs in virology and neuroscience. INFLUENZA: Principal driver of program SAR. Played a key role in many aspects of the research that successfully drove the program from early- to full-phase, and ultimately to proof of concept studies. BACE-1: A leading contributor to a neuroscience program directed at the identification of BACE-1 inhibitors. Made key contributions to the development of program SAR that lead directly in a successful DP2 transition to full-phase. Remained on the full-phase effort and continued to make key contributions. GAMMA-SECRETASE: Lead my team in the rapid evaluation of multiple chemotypes for a full-phase program directed at the identification of Gamma-secretase inhibitors. My team employed solid phase and solution methods for library generation and data from these efforts helped the team to identify an early candidate nomination (ECN) for clinical evaluation. HIV RNase H My team identified the first internally confirmed RNase H inhibitors that were non-cytotoxic, exhibited excellent cellular potency and displayed resistance against mutant RNase H enzyme. LIBRARY DESIGN and SYNTHESES: Lead a chemistry team in the design and syntheses of large libraries using extensive solid-phase methodologies. Also directed efforts on the syntheses of smaller focused-libraries for lead optimization.



IRORI

• San Diego

• Senior scientist

  • 1996 - 1999

  Senior Research Scientist in Combinatorial and Synthetic Chemistry • Involved in developing novel materials and RF Tag Microkan technology that was widely used for solid phase synthesis in pharmaceutical industry. • Efficiently made first two libraries to start collaborations between IRORI and other pharmaceutical companies Senior Research Scientist in Combinatorial and Synthetic Chemistry • Involved in developing novel materials and RF Tag Microkan technology that was widely used for solid phase synthesis in pharmaceutical industry. • Efficiently made first two libraries to start collaborations between IRORI and other pharmaceutical companies